Cutaneous Warts Clinical Trial
Official title:
bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients
As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05739786 -
Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts
|
Phase 1 | |
| Completed |
NCT02106260 -
First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts
|
Phase 1/Phase 2 | |
| Completed |
NCT03846648 -
CyPep-1 in Cutaneous Warts
|
Phase 1 | |
| Not yet recruiting |
NCT05902624 -
Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts
|
Early Phase 1 | |
| Completed |
NCT02333643 -
A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.
|
Phase 2 | |
| Completed |
NCT05023408 -
Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts
|
Phase 2 | |
| Completed |
NCT05862441 -
A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts
|
Phase 2/Phase 3 | |
| Completed |
NCT03734003 -
Infrared Bioeffect System for the Treatment of Cutaneous Warts
|
N/A |